Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL): Mechanistic basis and preliminary clinical experience

Esther Tahover, Rachel Bar-Shalom, Eli Sapir, Raphael Pfeffer, Igor Nemirovsky, Yehonatan Turner, Maya Gips, Patricia Ohana, Benjamin W. Corn, Andrew Z. Wang, Alberto A. Gabizon

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting.

Original languageEnglish (US)
Article number544
JournalFrontiers in Oncology
Volume8
Issue numberNOV
DOIs
StatePublished - 2018
Externally publishedYes

Keywords

  • Colorectal cancer
  • Liposomes
  • Mitomycin-C
  • Oligometastases
  • Prodrug
  • Radiosensitizer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL): Mechanistic basis and preliminary clinical experience'. Together they form a unique fingerprint.

Cite this